Skip to content

#Psilocybin

17 NovTue
  1. Psychedelic Alpha78

    Helus Pharma reports positive topline results from first phase 3 trial of HLP003 in major depressive disorder

    Helus Pharma, formerly Cybin, announced a positive topline readout from its first phase 3 study of HLP003, a deuterated psilocin analog, for the adjunctive treatment of major depressive disorder (MDD). The trial is part of the company's PARADIGM phase 3 program, which tests HLP003 as an adjunctive treatment in adults who have had an inadequate response. The announcement gives no effect size, adverse event data or participant numbers.

9 NovMon
  1. Psychedelic Alpha80

    Compass Pathways submits COMP360 psilocybin new drug application to FDA for treatment-resistant depression

    Compass Pathways announced it has submitted a new drug application to the FDA for its COMP360 psilocybin for treatment-resistant depression (TRD). The FDA is now reviewing three psychedelic applications, after Resilient Pharmaceuticals resubmitted its MDMA for PTSD application this summer and Usona Institute filed its psilocybin for major depressive disorder (MDD) package more recently. Compass said its package includes data from more than 1,000 participants, and the company is targeting an H1 2027 launch.

    Why it matters: With three psychedelic applications now before the FDA, the agency's next steps on COMP360 will show how it handles a package drawn from more than 1,000 participants.

5 NovThu
2 NovMon
  1. ClinicalTrials.gov: newly registered trials60

    NYU Langone registers trial of psilocybin-assisted psychotherapy for fear of cancer recurrence in early-stage breast cancer

    NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.

    Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.